Experimental CRISPR therapy cuts bad cholesterol by over 50 per cent for a year

CTX310 cut bad LDL cholesterol by over 50 per cent. AI GENERATED REPRESENTATION PIC

In a Phase 1 Cleveland Clinic trial, a single infusion of an experimental gene editing therapy called CTX310 cut bad LDL cholesterol by over 50 per cent for a full year.

By using CRISPR technology to deactivate the ANGPTL3 gene in the liver, the single-dose treatment also reduced triglycerides by 47.8 per cent.

Tested on patients with severe lipid disorders, the therapy caused no safety issues, offering promising protection against heart disease.

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever